Ocular Therapeutix, Inc. (OCUL) Balance Sheet

The balance sheet shows a clear pattern of episodic equity raises followed by rapid cash consumption. Total assets peaked at $808.1M in 2025Q4, but by 2026Q2 they had contracted to $671.3M, a 17% decline in two quarters. This trajectory suggests the company is deliberately front-loading clinical spending, but the pace of burn implies the current cash cushion may only last through the NDA submission in Q4 2026, assuming no additional capital raises.

The debt-to-equity ratio has improved from 0.30 in 2025Q3 to 0.15 in 2026Q2, driven by the equity raise rather than debt repayment. The absolute debt level is small relative to the $598.6M cash position, suggesting the company is not reliant on debt markets for funding. However, the stability of the debt balance over ten quarters implies it may be a term loan with fixed maturities, and the low leverage provides a cushion against clinical setbacks.

The balance sheet shows no goodwill, which is typical for a biotech that has grown organically. PPE has increased modestly from $15.3M in 2024Q4 to $25.3M in 2026Q2, likely reflecting investments in manufacturing capacity for commercial products. The low PPE intensity suggests that the company's competitive advantage is not tied to physical assets but to its hydrogel platform and clinical data, which are not capitalized on the balance sheet.

The equity base has been artificially inflated by large capital raises, as evidenced by the $400M increase in cash during 2025Q4. Retained earnings have become more negative, from -$762.4M in 2024Q1 to -$1.3B in 2026Q2, reflecting cumulative losses that outpace any revenue generation. This suggests that the company's book value is not a reliable indicator of intrinsic value, and investors should focus on the cash runway and clinical milestones rather than equity metrics.

Liquidity appears robust on the surface, with a current ratio well above 10 and cash covering over 40 times quarterly operating expenses. However, the burn rate is not constant; it has been increasing as R&D spending ramps up. Based on the latest quarter's operating cash outflow of approximately $70M, the cash balance would last about 8.5 quarters, which is sufficient to reach the NDA submission but leaves little margin for delays or additional trial costs.